There is now a specific treatment for patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations – amivantamab (Rybrevant).
Medscape Medical News
FDA OKs First Targeted Therapy for Subset of Patients With NSCLC
There is now a specific treatment for patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations – amivantamab (Rybrevant).
Medscape Medical News
